The value of the CRP-albumin-lymphocyte index (CALLY index) as a prognostic biomarker in acute ischemic stroke

CRP-白蛋白-淋巴细胞指数(CALLY指数)作为急性缺血性卒中预后生物标志物的价值

阅读:1

Abstract

This study aims to evaluate the predictive capability of CRP-albumin-lymphocyte (CALLY) index in relation to hemorrhagic transformation (HT) and functional outcome in acute ischemic stroke (AIS). A total of 439 AIS patients were included in this analysis. Multivariate logistic regression was conducted to examine the relationship between the CALLY index, HT, and functional outcomes. To address its non-linear association, a restricted cubic spline (RCS) model identified an optimal threshold for the CALLY index. Subgroup analyses further explored the association between the CALLY index and HT. The receiver operating characteristic (ROC) curve, the net reclassification index (NRI), and the integrated discrimination index (IDI) were used to assess and compare the predictive performance of the CALLY index with established models for HT. Furthermore, mediation analysis was performed to elucidate the causal pathways linking the CALLY index, HT, and functional outcomes. Among the participants, 9.79% (43/439) experienced HT, and 49.32% (182/369) encountered adverse outcomes. A higher CALLY index was associated with a lower risk of developing HT (OR 0.449, 95% CI 0.283-0.713) and poor outcome (OR 0.691, 95% CI 0.558-0.855). RCS curves demonstrated an increased risk of HT when the CALLY index fell below 1.188. Compared to existing HT prediction models, the CALLY index demonstrates superior predictive performance, with an AUC of 0.746. Furthermore, the CALLY index exhibits improved reclassification ability, as indicated by enhanced NRI and IDI values. The CALLY index independently predicts HT and adverse outcomes in AIS, demonstrating superior accuracy to existing risk scores and offering a practical biomarker for clinical prognosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。